Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece

Table 3 Distribution of MIC50/MIC90 values and resistance/nonsusceptibility rates per geographic region

City/Prefecture	# strains		PG	CXM	CTX	ERY	COT	TET	CIP
Athens.		%ns-%r	37.9–15.8	29.8–28.7	1.8–0.4	33.2–32.1	43.6–26	24.2–23.4	3.8
Attika	273	MIC50/MIC90	0.023–2	0.047–4	0.023–0.75	0.125–256	0.5–32	0.125–24	0.75–1.5
Halkida.		%ns-%r	37–15.2	23.9–21.7	1.4–0	39.1–37.7	51.8–29.2	34.8–30.4	3.8
Evia	138	MIC50/MIC90	0.023–2	0.032–3	0.023–0.75	0.125–256	0.75–32	0.19–32	0.75–2
Thessaloniki.		%ns-%r	32.8–7.4*	21.3–18	0.8–0	34.2–34.2	38–29.8	21.3–20.5	3.3
Central Macedonia	122	MIC50/MIC90	0.032–1	0.032–2	0.016–0.5	0.125–24	0.5–32	0.25–48	0.75–1.5
Ioannina.		%ns-%r	19.2-7.7	11.5–11.5	2.9–0	42.3–38.5	42.3–19.2	19.2–19.2	0
Epirus	26	MIC50/MIC90	0.032–1	0.047–3	0.023–0.38	0.25–96	0.5–18	0.125–24	0.5–1
Alexandroupolis.		%ns-%r	11.8-8.8	8.8–8.8	0–0	17.6*-17.6	35.3–2.9	14.7–11.8	11.8
Thrace	34	MIC50/MIC90	0.023–1	0.023–2	0.023–0.5	0.125–2.5	0.38–2	0.125–24	1–3
Herakleion.		%ns-%r	53.8-25.5	40.4–34.6	0–0	66.7*-66.7	65.4–26.9	48.1–46.2	6.1
Crete	52	MIC50/MIC90	0.12–2	0.5–6	0.12–0.75	32–256	1–32	1.5–96	0.75–1.5
Nafplio-Tripoli-Sparti.		%ns-%r	28.0-14.0	24.0–24.0	1.0–0.0	14.0*-14.0	30.0–20.0	21.0–21.0	2.0
Peloponnese	101	MIC50/MIC90	0.023–2	0.023–2	0.023–0.75	0.094–128	1–2	0.125–24	0.75–2
Greece in total	*746*	%ns-%r	34.8–14.1	25.7–23.9	1.3–0.1	33.8–33	43.8–25.2	26.3–24.8	4.0
		MIC50/MIC90	0.023–1.5	0.032–3	0.023–0.75	0.125–256	0.5–32	0.125–24	0.75–2

No resistance was recorded for levo- and moxi-floxacin. Respective MIC50/90 values were 0.75–1 and 0.125–0.19 mg/L
PG: penicillin. CXM: cefuroxime. CTX: ceftriaxone. ERY: erythromycin. COT: cotrimoxazole. TET: tetracycline. CIP: ciprofloxacin
*flags statistically significant differences at p level of = 0.05 when compared to Attika region

ISSN: 1471-2334